COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN VERSUS RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION USING REAL-WORLD EVIDENCE IN MEDICARE BENEFICIARIES

被引：0
|
作者：
Peng, S. [1 ]
Deger, K. [1 ]
Ustyugova, A., V [2 ]
Gandhi, P. [3 ]
Qiao, N. [1 ]
Wang, C. [3 ]
Kansal, A. [1 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV61
引用
收藏
页码：A269 / A270
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran
    Tajik, Amirmohammad
    Abbasi, Azam
    Goudarzi, Zahra
    Izadi-Moud, Azadeh
    Varmaghani, Mehdi
    CLINICAL CARDIOLOGY, 2024, 47 (06)
  • [42] A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia
    Alosaimi, Hind M.
    Alqahtani, Saeed
    Balkhi, Bander
    Alqahtani, Mishari
    Alzamil, Faisal
    Alhossan, Abdulaziz
    Alqahtany, Fatmah S.
    Alharbi, Abdullah A.
    Alqahtani, Nawaf Abdullah
    Albackr, Hanan
    Elgohary, Ghada
    Algahtani, Farjah H.
    PEERJ, 2022, 10
  • [43] REAL-WORLD DATA COST-EFFECTIVENESS OF DIRECT ORAL ANTICOAGULANTS COMPARED WITH ACENOCOUMAROL FOR THE MANAGEMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Gorostiza, I
    Bilbao, A.
    Mar, J.
    VALUE IN HEALTH, 2024, 27 (12) : S68 - S68
  • [44] Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
    Kjerpeseth, Lars J.
    Selmer, Randi
    Ariansen, Inger
    Karlstad, Oystein
    Ellekjaer, Hanne
    Skovlund, Eva
    PLOS ONE, 2019, 14 (08):
  • [45] The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
    van Hulst, Marinus
    Stevanovic, Jelena
    Jacobs, Maartje S.
    Tieleman, Robert G.
    Kappelhoff, Bregt
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (01) : 38 - 46
  • [46] Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis
    Ashley Prentice
    Irene Ruiz
    Erin R. Weeda
    Journal of Thrombosis and Thrombolysis, 2020, 49 : 360 - 364
  • [47] Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis
    Prentice, Ashley
    Ruiz, Irene
    Weeda, Erin R.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 49 (03) : 360 - 364
  • [48] Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
    Calderon, Jose Miguel
    Martinez, Fernando
    Diaz, Javier
    Fernandez, Antonio
    Sauri, Inmaculada
    Uso, Ruth
    Trillo, Jose Luis
    Vela, Sara
    Bea, Carlos
    Redon, Josep
    Forner, Maria Jose
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8
  • [49] Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
  • [50] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS
    de Andres-Nogales, F.
    Gay-Pobes, P. R.
    Ines, M.
    Polanco Sanchez, C.
    Alves, D.
    Oyaguez, I
    VALUE IN HEALTH, 2019, 22 : S549 - S550
12345